November 20, 2015

Kissei Announces Licensing Agreement with ObsEva SA for KLH-2109, a Novel Investigational Drug for the Treatment of Endometriosis

Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co, Ltd. (Head Office: Matsumoto-city, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa) announced today that it concluded an agreement granting exclusive rights to ObsEva SA (Head Office: Geneva, Switzerland; Co-Founder and CEO: Ernest Loumaye) to develop and commercialize a novel investigational drug with the development code KLH-2109 (hereinafter "Agent"), for the treatment of endometriosis. The Agent was discovered by Kissei.

Under this agreement, Kissei Pharmaceutical grants ObsEva SA exclusive worldwide rights on the Agent, excluding some countries in Asia such as Japan. Kissei Pharmaceutical will receive an upfront payment; will be eligible to receive milestone payments according to stages of development; and will supply the drug substance to ObsEva SA.

The Agent is a novel orally administrable GnRH (gonadotropin releasing hormone) antagonist which acts by antagonizing GnRH at the GnRH receptor in the pituitary and consequently suppressing the secretion of gonadotropin. The Agent is currently under Phase 2 clinical trials in Japan.

Kissei Pharmaceutical focuses on drug discovery, research and development of new drugs, and aims at international expansion by licensing out of the original products. Kissei will continue to contribute to the health of people around the world through developing new drugs.

〈About ObsEva〉
Name: ObsEva SA
Head Office: Geneva, Switzerland
Establishment: November, 2012
CEO: Ernest Loumaye
ObsEva is a clinical stage company. Their lead programs target the increasing but underserved problems of obstetrics and gynecology affecting women worldwide. For more information about ObsEva SA, please refer to the official website <>.